In a double-blind, placebo-controlled, parallel group study in adult patients with detrusor overactivity associated with a neurologic condition and restrictive lung disease of neuromuscular etiology [defined as FVC 50-80% of predicted value in patients with spinal cord injury between C5 and C8, or MS] the event rate in change of Forced Vital Capacity ≥15% or ≥20% was generally greater in patients treated with BOTOX than in patients treated with placebo (see Table 6).
Two double-blind, placebo-controlled, randomized, multi-center clinical studies were conducted in patients with urinary incontinence due to detrusor overactivity associated with a neurologic condition who were either spontaneously voiding or using catheterization (Studies NDO-1 and NDO-2). A total of 691 spinal cord injury (T1 or below) or multiple sclerosis patients, who had an inadequate response to or were intolerant of at least one anticholinergic medication, were enrolled. These patients were randomized to receive either 200 Units of BOTOX (n=227), 300 Units of BOTOX (n=223), or placebo (n=241).
It’s been a little over three weeks. The neurologist said that after two weeks, my migraines and headaches should be substantially reduced. I haven’t spoken about it much even to people close to me because I didn’t want to jinx it, but right around the two-week mark, my headaches faded. I did have a migraine the day after the injections, followed by a lingering headache for about a week, but my neurologist didn’t think it was caused by the Botox. I know my body and have a feeling it was, especially because the introduction or removal of medication can exacerbate lupus symptoms and flares, so I was put on a prednisone taper just to be safe.
Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV. Learn more about Thomson Reuters products:
IntimatesBras,Lingerie,Lounge & Sleepwear,Panties...3831 Maternity ClothingMaternity Activewear,Maternity Bottoms,M...391 Plus Size ClothingPlus Size Activewear,Plus Size Bottoms,P...1615 Women's AccessoriesWomen's Belts,Women's Eyewear,Women's Gl...8529 Women's ClothingDresses,Leggings,Skirts,Sweaters & Cardi...40957 Women's ShoesBoots & Booties,Pumps & Heels,Women's At...2800

Botulinum toxin is used to treat certain eye disorders such as crossed eyes (strabismus) and uncontrolled blinking (blepharospasm), to treat muscle stiffness/spasms or movement disorders (such as cervical dystonia, torticollis), and to reduce the cosmetic appearance of wrinkles. It is also used to prevent headaches in people with very frequent migraines. Botulinum toxin relaxes muscle by blocking the release of a chemical called acetylcholine.
Do not receive BOTOX® Cosmetic if you: are allergic to any of the ingredients in BOTOX® Cosmetic (see Medication Guide for ingredients); had an allergic reaction to any other botulinum toxin product such as Myobloc® (rimabotulinumtoxinB), Dysport® (abobotulinumtoxinA), or Xeomin® (incobotulinumtoxinA); have a skin infection at the planned injection site.
×